VEPESID CAPSULE
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
18-12-2019
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ETOPOSIDE
Tillgänglig från:
CHEPLAPHARM ARZNEIMITTEL GMBH
ATC-kod:
L01CB01
INN (International namn):
ETOPOSIDE
Dos:
50MG
Läkemedelsform:
CAPSULE
Sammansättning:
ETOPOSIDE 50MG
Administreringssätt:
ORAL
Enheter i paketet:
20
Receptbelagda typ:
Prescription
Terapiområde:
ANTINEOPLASTIC AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0114567001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2008-08-12
Produktens egenskaper
PRODUCT MONOGRAPH
PR VEPESID*
(Etoposide Capsules)
Capsule, 50 mg
ANTINEOPLASTIC AGENT
Date of Revision:
December 18, 2019
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24, 17489 Greifswald, Germany
* Registered TM of CHEPLAPHARM Arzneimittel GmbH
Distributed by Xediton Pharmaceuticals Inc,
2000 Argentia Rd, Mississauga, Ontario L5N 1W1
Submission Control Number: 233295
TABLE OF CONTENT
THERAPEUTIC CASSIFICATION
..............................................................................................
3
ACTIONS AND CLINICAL PHARMACOLOGY
..........................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
4
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS
...............................................................................................................................
4
PRECAUTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.............................................................................................................
7
ADVERSE REACTIONS
............................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
..............................................................10
DOSAGE AND ADMINISTRATION
...........................................................................................11
PHARMACEUTICAL INFORMATION
.......................................................................................12
SPECIAL INSTRUCTIONS
.......................................................................................................13
AVAILABILITY OF DOSAGE FORMS
.......................................................................................13
HUMAN PHARMACOLOGY
........................................
Läs hela dokumentet
